Drug Res (Stuttg) 2017; 67(03): 149-155
DOI: 10.1055/s-0042-118448
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Novel 99mTc-Radiolabeled Anionic Linear Globular PEG-Based Dendrimer-Chlorambucil: Non-Invasive Method for In-Vivo Biodistribution

Seyedeh Masoomeh Ghoreishi
1   Faculty of Pharmacy, Department of Radiopharmacy, Tehran University of Medical Sciences, Tehran, Iran
,
Ali khalaj
1   Faculty of Pharmacy, Department of Radiopharmacy, Tehran University of Medical Sciences, Tehran, Iran
,
Ahmad Bitarafan-Rajabi
2   Department of Nuclear Medicine, Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
,
Amir Darbandi Azar
2   Department of Nuclear Medicine, Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
,
Mehdi Shafiee Ardestani
1   Faculty of Pharmacy, Department of Radiopharmacy, Tehran University of Medical Sciences, Tehran, Iran
,
Artin Assadi
1   Faculty of Pharmacy, Department of Radiopharmacy, Tehran University of Medical Sciences, Tehran, Iran
› Author Affiliations
Further Information

Publication History

received 23 March 2016

accepted 09 May 2016

Publication Date:
19 December 2016 (online)

Abstract

Chlorambucil (CBL) is an alkylating agent, which widely use in the treatment of various types of tumors. The main purpose of this study is to evaluate the in-vivo biodistribution of CBL conjugated to the anionic dendrimer, which has a great ability to labeled with 99mTc through binding to carboxylate terminate groups. Whole body scans were used to analyze the percentage of the injected dose in different times. Radiochemical purity (RCP) and in-vivo biodistribution were also calculated with the SPECT/CT instrument. Our study proposes a new method for RCP determination and shows that this carrier is a promising agent to complex with the 99mTc and biological assessment.

 
  • References

  • 1 Jain K, Jain NK. Surface engineered dendrimers as antiangiogenic agent and carrier for anticancer drug: dual attack on cancer. Journal of nanoscience and nanotechnology 2014; 14: 5075-5087
  • 2 Kojima C, Kono K, Maruyama K et al. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate Chemistry 2000; 11: 910-917
  • 3 Singh P, Gupta U, Asthana A et al. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 2008; 19: 2239-2252
  • 4 Namazi H, Toomari Hamrahloo Y. Novel PH sensitive nanocarrier agents based on citric acid dendrimers containing conjugated β-cyclodextrins. Advanced Pharmaceutical Bulletin 2011; 1: 40-47
  • 5 Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Progress in Polymer Science 2014; 39: 268-307
  • 6 Zhao J, Zhou R, Fu X et al. Cell-penetrable lysine dendrimers for anti-cancer drug delivery: synthesis and preliminary biological evaluation. Archiv der Pharmazie 2014; 347: 469-477
  • 7 Hu J, Su Y, Zhang H et al. Design of interior-functionalized fully acetylated dendrimers for anticancer drug delivery. Biomaterials 2011; 32: 9950-9959
  • 8 Bielawski K, Bielawska A, Muszyńska A et al. Cytotoxic activity of G3 PAMAM-NH2 dendrimer-chlorambucil conjugate in human breast cancer cells. Environmental Toxicology and Pharmacology 2011; 32: 364-372
  • 9 Namazi H, Adeli M. Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents. Biomaterials 2005; 26: 1175-1183
  • 10 Naeini AT, Adeli M, Vossoughi M. Poly(citric acid)-block-poly(ethylene glycol) copolymers – new biocompatible hybrid materials for nanomedicine. Nanomedicine: Nanotechnology, Biology and Medicine 2010; 6: 556-562
  • 11 Giray S, Bal T, Kartal AM et al. Controlled drug delivery through a novel PEG hydrogel encapsulated silica aerogel system. Journal of biomedical materials research Part A 2012; 100: 1307-1315
  • 12 Jain K, Kesharwani P, Gupta U et al. Dendrimer toxicity: Let’s meet the challenge. International journal of pharmaceutics 2010; 394: 122-142
  • 13 Altiparmak B, Lambrecht FY, Bayrak E et al. Design and synthesis of 99mTc-citro-folate for use as a tumor-targeted radiopharmaceutical. International journal of pharmaceutics 2010; 400: 8-14
  • 14 Ghalandarlaki N, Mohammadi TD, Agha Babaei R et al. Gd3+-DTPA-bis (N-methylamine) - anionic linear globular Dendrimer-G1; a more efficient MRI contrast media. Drug research 2014; 64: 57-65
  • 15 Masta A, Gray PJ, Phillips DR. Nitrogen mustard inhibits transcription and translation in a cell free system. Nucleic Acids Research 1995; 23: 3508-3515
  • 16 Begleiter A, Mowat M, Israels LG et al. Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leukemia & lymphoma 1996; 23: 187-201
  • 17 Bell RA, Hughes DW, Lock CJL et al. The synthesis and high-resolution NMR spectroscopy of ethyl N-(2-triphenylmethylthio)ethanoyl-O-{4′-[4″-(1″-bis(2″′-chloroethyl)amino)phenyl]butanoyl}-L-seryl-S-benzyl-L-cysteine: a chelate-chlorambucil complex for use as a ligand for 99mTc radio-imaging. Canadian Journal of Chemistry 1996; 74: 1503-1511
  • 18 Kiesewetter DO, Jagoda EM, Kao C-HK et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nuclear Medicine and Biology 2003; 30: 11-24
  • 19 Satpati D, Korde A, Venkatesh M et al. Preparation and bioevaluation of a 99mTc-labeled chlorambucil analog as a tumor targeting agent. Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine 2009; 67: 1644-1649
  • 20 Gangloff A, Hsueh WA, Kesner AL et al. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2005; 46: 1866-1871
  • 21 Assadi A, Najafabadi VS, Shandiz SA et al. Novel conjugated chlorambucil- anionic linear globular peg based dendrimer second generation: In Vitro/In Vivo improved anticancer activity. OncoTargets and Therapy
  • 22 Dapueto R, Castelli R, Fernández M et al. Biological evaluation of glucose and deoxyglucose derivatives radiolabeled with [99mTc(CO)3(H2O)3]+ core as potential melanoma imaging agents. Bioorg Med Chem Lett 2011; 21: 7102-7106
  • 23 Russell CD, Speiser A. Complexes of technetium with hydroxycarboxylic acids: gluconic, glucoheptonic, tartaric, and citric. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 1980; 21: 1086-1090
  • 24 Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine: nanotechnology, biology, and medicine 2005; 1: 193-212
  • 25 Madaan K, Kumar S, Poonia N et al. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. Journal of Pharmacy & Bioallied Sciences 2014; 6: 139-150
  • 26 Cheng Y, Xu Z, Ma M et al. Dendrimers as drug carriers: Applications in different routes of drug administration. Journal of Pharmaceutical Sciences 2008; 97: 123-143
  • 27 Kesner AL, Dahlbom M, Huang SC et al. Semiautomated analysis of small-animal PET data. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2006; 47: 1181-1186
  • 28 Mehdi Mirzaei MM, Shahbazi-Gahrouei D. Synthesis and development of Gd3+-ALGDG2-C595 as MR imaging contrast Agent. Journal of Biomaterials and Nanobiotechnology 2013; 4: 22-29
  • 29 Amin AMF, NS AbdEl-Bary A. Iodine-125-Chlorambucil as possible radio anticancer for diagnosis and therapy of cancer: Preparation and tissue distribution. British Journal of Pharmaceutical Research 2014; 4: 1873-1885